Prevalence of antibodies to Hepatitis C virus among Nigerian patients with HIV infection

Uchenna Inyama, Petrus and Jesse Uneke, Chigozie and Ike Anyanwu, Greg and Moses Njoku, Okonkwo and Hauwa Idoko, Julia (2005) Prevalence of antibodies to Hepatitis C virus among Nigerian patients with HIV infection. [Journal (On-line/Unpaginated)]

Full text available as:



Nigeria belongs to the group of countries highly endemic for viral hepatitis; unfortunately information on the prevalence of hepatitis C amongst patients with HIV in Nigeria is very scarce. This hospital-based investigation was conducted at two major hospitals in Jos, Nigeria from June 2002 through May 2003. Serum samples from 490 confirmed HIV infected patients were assayed for the presence of antibodies to HCV, using a third generation enzyme linked immunosorbent assay. Twenty eight (5.7%; 95% CI 3.66-7.76%) of the patients had antibodies to HCV. The prevalence of HCV antibodies was higher among the males (7.5%; 95% CI 3.83-11.09%) than the females (4.5%; 95% CI 2.10-6.88%). Statistical analysis showed no significant difference (x2 = 1.917, df =1, p=0.05). Individuals of the age group 41-50 years had the highest prevalence of HCV antibodies (15.4%; 95% CI. 7.37-23.29%), followed by those of age group 31-40 years (7.4%; 95%, CI 3.70-11.20%). A significant difference was observed in the association between age and prevalence of HCV antibodies (x2 = 24.151, df = 4, p =0.05). Early diagnosis of HCV in people with HIV infection is advocated to reduce risk of HCV related advanced liver disease.

Item Type:Journal (On-line/Unpaginated)
Keywords:Hepatitis C virus, HIV, Nigeria
Subjects:JOURNALS > Online Journal of Health and Allied Sciences
ID Code:4551
Deposited By: Kakkilaya Bevinje, Dr. Srinivas
Deposited On:20 Oct 2005
Last Modified:11 Mar 2011 08:56

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Choo QL, Kuo G, Weiner AJ et al. Isolation of CDNA alone derived from a blood borne non A- non B hepatitis. Science 1989;224:359-62.

2. Albert A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999;31:17-24.

3. Seef LB. Natural history of hepatitis C. Am J Med 1999;107:10-15.

4. Highleyman L. HIV and hepatitis C coinfection. BETA 2003;15:32-44.

5. Piliero PJ, Faragon JJ. Case report. Hepatitis B virus and HIV coinfection. AIDS Read 2002;12:443-4, 448-51

6. Mutimer DJ, Olomu A, Skidmore S et al. Viral hepatitis in Nigeria -sickle cell disease and commercial blood donors. Q J Med 1994;87:407-11.

7. Federal Ministry of Health Nigeria. National HIV/AIDS and Reproductive Health Survey. Federal Ministry of Health Abuja, Nigeria. 2004:1-4.

8. Halim NK, Ajayi OI. Risk factors and seroprevalence of hepatitis C antibody in blood donors in Nigeria. East Afr Med J. 2000;77:410-12.

9. Lesi OA, Kehinde MO. Hepatitis C virus infection in patients with sickle cell aanemia at the Lagos University Hospital. Niger Postgrad Med J 2003;10:79-83.

10. Halim NKD, Offor E, Ajayi OI. Epidemiologic study of the seroprevalence of hepatitis-B surface antigen (HBsAg) and HIV-1 in blood donors. Nig J Clin Pract 1992;2:42-5.

11. Baba MM, Gashau W, Hassan AW. Detection of hepatitis-B surface antigenaemia in patients mirth and without the manifestations of AIDS in Maiduguri, Nigeria. Nig Postgrad Med J 1998;5:125-8.

12. United Nations System in Nigeria. Nigeria Common Country Assessment: HIV/AIDS. World Health Organization, Geneva. 2001:141-216.

13. Ockenga J, Stoll M, Tillmann HL, Trautwein C, Manns MP, Schmidt RE. Coinfection of hepatitis B and C in HIV infected patients. Wien Med Wochenschr 1997;471:439-42.

14. Amin J, Kaye M, Skidmore S, Pillay D, Cooper D, Dore G. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004; 5:174-9.

15. Segurado AC, Braga P, Etzel A, Cardoso MR. Hepatitis C virus coinfection in a cohort of HIV-infected individuals from Santos Brazil: seroprevalence and associated factors. AIDS Patient Care STDS 2004;18:135-43.

16. Dimitrakopoulos A, Takou A, Haida A, Molangeli S, Gialeraki A, Kordossis T. The prevalence of hepatitis B and C in HIV-positive Greek patients; relationship to survival of deceased AIDS patients. J Infect 2000;40:127-31.

17. Lincoln D, Petoumenos K, Dore G J. HIV/HBV and HIV/HCV coinfection and outcomes following highly active antiretroviral therapy. HIV Med 2003;4:241-9.

18. Veruccli G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004;32:33-46.

19. Koziel MJ. New Insights in HIV and hepatitis C virus coinfection. Top HIV Med 2002;10:16-21.

20. Dienstag JL. Isselbacher KJ. Acute viral hepatitis. In: Fauci AS, Braunwald E, Isselbacher KJ, eds. Harrison's Principles of Internal Medicine, 14th edn. New York, Mc Graw-Hill, 1998;72-92.

21. Osmond DH. HIV Disease progression from infection to CDC-defined AIDS. In Cohen PT, Sande MA, Volberding PA eds. The AIDS Knowledge Base. New York, Little, Brown and company. 1994:1.7:1-1.7:19.

22. Drosten C, Nippraschk T, Manegold C, Meised H, Brixner V, Roth WK, Apedjinou A, Gunther S. Prevalence of hepatitis B virus DNA in anti-HBc- positive / HBsAg negative sera correlates with HCV but not HIV serostatus. J Clin Virol 2004;29:59-68.


Repository Staff Only: item control page